Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures

Wang, K; Schutze, I; Gulde, S; Bechmann, N; Richter, S; Helm, J; Lauseker, M; Maurer, J; Reul, A; Spoettl, G; Klink, B; William, D; Knosel, T; Friemel, J; Bihl, M; Weber, A; Fankhauser, M; Schober, L; Vetter, D; Dappen, MB; Ziegler, CG; Ullrich, M; Pietzsch, J; Bornstein, SR; Lottspeich, C; Kroiss, M; Fassnacht, M; Wenter, VUJ; Ladurner, R; Hantel, C; Reincke, M; Eisenhofer, G; Grossman, AB; Pacak, K; Beuschlein, F; Auernhammer, CJ; Pellegata, NS; Nolting, S

Nolting, S (通讯作者),Ludwig Maximilian Univ Munich, Univ Hosp, Dept Internal Med 4, LMU Klinikum, Munich, Germany.;Nolting, S (通讯作者),Univ Hosp Zurich USZ, Dept Endocrinol Diabetol & Clin Nutr, Zurich, Switzerland.;Nolting, S (通讯作者),Univ Zurich UZH, Zurich, Switzerland.

ENDOCRINE-RELATED CANCER, 2022; 29 (6): 285

Abstract

Aggressive pheochromocytomas and paragangliomas (PPGLs) are difficult to treat, and molecular targeting is being increasingly considered, but with var......

Full Text Link